Back to Search
Start Over
Adiponectin moderates antidepressant treatment outcome in the combining medications to enhance depression outcomes randomized clinical trial
- Source :
- Personalized Medicine in Psychiatry; August-September 2018, Vol. 9 Issue: 1 p1-7, 7p
- Publication Year :
- 2018
-
Abstract
- Major depressive disorder (MDD) is often comorbid with metabolic diseases such as obesity, cardiovascular disease, and type 2 diabetes. A potential link between these disorders is adiponectin, an adipocyte-derived circulating hormone with insulin-sensitizing, anti-inflammatory, and neuroplasticity effects. Reductions in plasma levels of adiponectin have been reported in both humans with depression and in the chronic-defeat mouse model of depression. However, the predictive value of adiponectin for treatment response to depression has not been determined.
Details
- Language :
- English
- ISSN :
- 24681717
- Volume :
- 9
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Personalized Medicine in Psychiatry
- Publication Type :
- Periodical
- Accession number :
- ejs46488669
- Full Text :
- https://doi.org/10.1016/j.pmip.2018.05.001